A study of SKB264 plus KL-A167 for MSI-H/dMMR gynecologic cancers
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs (SKB264 and KL-A167) for women with advanced ovarian, endometrial, or cervical cancer that has a specific genetic feature (MSI-H or dMMR). It aims to see if this combo can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced ovarian, endometrial, or cervical cancer that has spread or come back.
- Your tumor is MSI-H or dMMR (a specific genetic feature).
- You have already received at least one prior cancer treatment for your advanced disease.
- You are in good enough health to be up and about (ECOG 0 or 1), and your organs are working well.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—SKB264 and QL1706—for women with cervical cancer that has come back or spread and is not curable with standard treatments. The goal is to see if this new combination can help shrink tumors or slow the disease.
This trial is testing a combination of two drugs, Sac-TMT and KL-A167, in people with a certain type of advanced breast cancer (HR+/HER2-) that is PD-L1 positive. It's for those whose cancer has gotten worse after treatment with a CDK4/6 inhibitor and hormone therapy.
This trial tests two new medicines (SKB264 and KL-A167) given before surgery for people with a specific high-risk type of early-stage breast cancer (ER-positive, HER2-negative). The goal is to see if this combination can shrink tumors and improve outcomes.
This study tests a combination of two drugs—Sacituzumab Tirumotecan (Sac-TMT) and an immunotherapy called KL-A167—given before surgery to shrink triple-negative breast tumors. It aims to improve outcomes for people with early-stage, high-risk breast cancer who have not yet had any treatment.
This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.
This study is a real-world treatment trial for people with advanced HER2-negative breast cancer (either triple-negative or HR+/HER2-). It tests a drug called SKB264, given alone or with other therapies, and aims to see how well it works in everyday clinical practice.
Hear when a new Recurrent or Metastatic MSI-H/dMMR Gynecological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.